Statements (60)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Biology
|
| gptkbp:administered_by |
intravenous infusion
|
| gptkbp:approves |
gptkb:2006
gptkb:FDA |
| gptkbp:availability |
prescription only
|
| gptkbp:clinical_trial |
gptkb:Shire_Pharmaceuticals
multiple countries improved quality of life Phase III reduced symptoms safety profile established efficacy demonstrated improved enzyme levels |
| gptkbp:clinical_use |
long-term treatment
|
| gptkbp:condition |
lysosomal storage disorders
|
| gptkbp:contraindication |
active infections
severe allergic reactions severe liver disease severe kidney disease hypersensitivity to idursulfase |
| gptkbp:dosage_form |
gptkb:Software_Solutions
|
| gptkbp:duration |
lifelong
|
| gptkbp:financial_support |
available
|
| https://www.w3.org/2000/01/rdf-schema#label |
Elaprase
|
| gptkbp:ingredients |
gptkb:idursulfase
|
| gptkbp:is_monitored_by |
regular check-ups
|
| gptkbp:manufacturer |
gptkb:Shire_Pharmaceuticals
|
| gptkbp:marketed_as |
gptkb:Elaprase
|
| gptkbp:mechanism_of_action |
replaces deficient enzyme
|
| gptkbp:patient_education |
provided by manufacturer
|
| gptkbp:patient_population |
pediatric and adult patients
|
| gptkbp:price |
high
|
| gptkbp:project |
commercialized
|
| gptkbp:regulatory_compliance |
approved
|
| gptkbp:research_focus |
genetic disorders
long-term outcomes pediatric treatments enzyme replacement therapies lysosomal storage diseases |
| gptkbp:route_of_administration |
IV
|
| gptkbp:service_frequency |
weekly
|
| gptkbp:shelf_life |
24 months
|
| gptkbp:side_effect |
fatigue
headache muscle pain nausea fever vomiting urticaria rash joint pain chills anaphylaxis infusion reactions hypersensitivity reactions |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
gptkb:Mucopolysaccharidosis_II
|
| gptkbp:used_for |
gptkb:Hunter_syndrome
|
| gptkbp:bfsParent |
gptkb:Shire_plc
|
| gptkbp:bfsLayer |
5
|